tv.qiagenbioinformatics.com

Inflammatory Bowel Disease: Drug Target and Biomarker Investigation using...

Wed, 28 Jan 2026 21:55:09 GMT

In this 90-minute training using Inflammatory Bowel Disease (IBD) public data from NCBI GEO through Omicsoft DiseaseLand, attendees will learn how to:
• Rapidly query and identify public datasets that fit our search criteria
• Discover and validate biomarker expression in disease tissue, different treatments, and response groups
• Identify a list of biomarkers specific to responders vs non-responders
• Confirm condition-specific biomarkers through gene expression heatmaps
• Opportunity for live Q&A

April 1, 2020 - 1 - OmicSoft DiseaseLand Core Capabilities Training - Elodie...

Wed, 28 Jan 2026 21:50:31 GMT

Supporting Biomarker Discovery One Cell at a Time - Introduction to QIAGEN...

Mon, 25 Aug 2025 10:45:44 GMT

Single-cell gene expression analysis helps biologists and bioinformaticians reveal complex and rare cell populations, uncover regulatory relationships among genes and analyze and visualize gene expression differences among different cell types, or within a unique cell type. In this talk we will explore new tools for analyzing, interpreting and explore scRNA-seq data and the underlying biology. We will also show how to integrate ‘omics datasets from different platforms to gain insights into the biology and molecular drivers of specific cell populations.
Objectives:
How to analyze scRNA-seq data without a bioinformatician or learning code.
How to leverage automatic cell annotation to streamline your workflow.
How to quickly comb millions of cells to identify

Click here to learn more.

Drug Target and Biomarker Investigation using OmicSoft OncoLand

Mon, 25 Aug 2025 10:43:04 GMT

In this 90-minute training, attendees will learn how to use basic expression analysis functionalities in QIAGEN OmicSoft OncoLand. QIAGEN OmicSoft Single Cell Land will also be discussed, focusing on public single-cell data.

Key focus will be on Biomarker discovery with QIAGEN OmicSoft OncoLand leveraging public oncology data from GEO, TCGA and other collections to:

• Discover and validate biomarker expression in diseases, disease subtypes, treatments, cell types, etc.
• Identify a list of biomarkers specifically expressed in disease, treatment group, cell type or other condition of interest
• Overlay expression of a gene on cell clusters of interest from public single-cell data

This training is designed for biologists, bioinformaticians, and data scientists.

Checkpoint inhibitors investigation in context of biomarkers, drug targets...

Mon, 25 Aug 2025 10:42:38 GMT

This training will focus on how QIAGEN Omicsoft Studio and IPA can be used to discover new biomarkers, validate (or study) drug targets and identify novel mechanisms of action with user and/or public checkpoint inhibitor datasets from resources like GEO, SRA, TCGA and more.

In this training, you will learn how to:
· Investigate the expression of a gene/biomarker/drug target across different treatments and diseases
· Derive a biomarker/gene signature from a specific condition (for example, non-responders of a drug, a specific disease/disease subtype and more)
· Correlate expression of multiple genes and biomarkers
· Compare different experimental groups (user and/or public data) at both gene expression and pathways/regulatory networks activity levels

Drug treatment, toxicology and target safety assessment using QIAGEN IPA and...

Mon, 25 Aug 2025 10:40:29 GMT

In this 90-minute training, you’ll learn how to do drug treatment, toxicology and target safety assessment-related discoveries using QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN Omicsoft Lands.
Using public data from GTEx (normal tissue), GEO, cancer collections and more, you’ll learn how to use Omicsoft Lands to:
• Investigate a drug target or biomarker expression across different normal tissues, disease conditions, treatments and more
• Correlate expression of two or more genes
• Identify a list of genes or biomarkers specific to treatment, disease, normal tissue, cell type and more

Using findings from peer-reviewed publications and other sources, attendees we’ll explore with you how to use QIAGEN IPA to:
• Study the impact of targeting a gene/protein on different toxicological and biological functions
• Derive tox findings for a gene of interest from QIAGEN IPA’s knowledgebase
• Identify and study toxicity-related pathways, regulators and functions for an internal dataset or a public dataset
• Compare different drug treatments, other conditions or multi-omics data for novel discoveries

QIAGEN Biomedical KB-HD: data- and analytics-driven drug discovery

Tue, 14 May 2024 13:57:00 GMT

Ingenuity Pathway Analysis (IPA), currently cited in tens of thousands of publications and used by a large number of biopharmaceutical companies, is backed by QIAGEN Biomedical KB-HD. Accordingly, biomedical relationships knowledge has practically become required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications.

In this webinar, we will introduce Biomedical KB-HD and how it allows its users to tackle applications that are not feasible with the Ingenuity Pathway Analysis graphical user interface or can be done faster and with more flexibility programmatically. We will demonstrate queries such as

• Quickly find the shortest connections between genes/proteins/metabolites of interest in the context of specific disease through queries
• Systematically build a network given a short list of genes/proteins/metabolites/chemicals
• Recreate a drug mechanism of action

Integrating deeply curated omics data with APIs for biomarkers and drug...

Mon, 15 Apr 2024 09:24:11 GMT

This webinar is for data scientists and bioinformaticians who need extensive high-quality omics data to target discovery efforts. Learn how to programmatically discover, retrieve, filter, aggregate and analyze omics (RNA-seq, scRNA-seq, microarray, proteomics etc.) data from QIAGEN’s comprehensive repository of deeply curated multi-omics data. Attendees will learn how to leverage extensive metadata to find and combine datasets of interest, find and test signatures, and perform custom analyses to reveal disease-related patterns.

Join us to learn how QIAGEN OmicSoft Lands API can revolutionize your data analysis workflows and help you make more informed decisions. Topics to be covered:

• Search for gene signatures to find relevant datasets through Gene Set Analysis
• Identify the correlation of results
• Find multiple datasets with the same metadata (metadata refers to cell type, tissue, disease, drug treatment etc., associated with public data)
• Perform meta-analysis for novel discoveries
• Test cell specificity with custom aggregation

Leveraging expert-curated knowledge from COSMIC and QIAGEN to avoid pitfalls,...

Wed, 13 Mar 2024 13:05:09 GMT

The cancer drug discovery landscape is shifting. While research continues to grow in cost and complexity, the pace of development has never been faster. Biopharmaceutical companies can’t afford to waste time and resources pursuing ineffective or unsafe ideas.

In this talk, our experts discuss how biopharmaceutical companies can leverage key genomic, biomedical, and clinical trial databases to improve and accelerate cancer drug discovery while avoiding potential pitfalls. Through a series of use cases, attendees will learn about expert-curated knowledge from the Wellcome Sanger Institute and QIAGEN, and how to use these resources to better predict cancer-driving effects of mutations, identify available drugs that target specific variants, and accelerate indication expansion and repurposing of existing cancer therapies.

Learning objectives:

Examine use-cases of how to leverage expert-curated databases across multiple phases of cancer drug development.
Discover key applications of these databases, including determining the function, frequency, and actionability of specific mutations.
Discuss potential pitfalls and clinical consequences, and how to avoid them early with data-driven drug target and biomarker qualification.

Biomarker discovery, target validation, and variant identification using...

Thu, 29 Feb 2024 14:46:00 GMT

In this webinar, users will learn how to leverage solutions from QIAGEN Digital Insights to discover biomarkers, validate targets, and identify variants. Specifically, users will learn:
1. How to locate public studies of interest using OmicSoft DiseaseLand.
2. Investigate expression of genes of interest across different treatments, disease states, etc.
3. Identify variants of interest for candidate biomarkers and targets using Human Gene Mutation Database.
4. Leveraging the QIAGEN Knowledgebase in Ingenuity Pathway Analysis to explore and extend findings from OmicSoft DiseaseLand and Human Gene Mutation Database.
5. Learn about additional methods to access data from OmicSoft, Human Gene Mutation Database, and Ingenuity Pathway Analysis for data scientists.

Target exploration and cell line selection for drug discovery

Mon, 18 Dec 2023 12:11:18 GMT

Cancer cell line models have been a cornerstone of cancer research for decades. Profiling cancer cell lines can be a powerful tool to identify gene alterations or cancer-related pathways and aid in discovering putative drug targets. In this webinar, we'll use QIAGEN OmicSoft Lands and QIAGEN Ingenuity Pathway Analysis (IPA) to help you select cell lines and translate insights from your cell line experiments for drug target discovery.

During this 90-minute discussion, we'll explore how you can use these software tools to:
• Select appropriate cancer cell lines for a variety of applications such as drug discovery, precision disease modeling, understanding gene function in cancer, immune-oncology research and more
• Examine various 'omics data for genes of interest for expression, mutation, hotspots and gene dependency data
• Generate networks for hypotheses and test them in silico to improve the translation of insights derived from cell line models to the drug target identification
• Integrate analyses of public 'omics data and drug response phenotypes using cell line model systems by exploring data from the Library of Integrated Network-Based Cellular Signatures (LINCS)
• Prioritize drug targets and profile phenotypic/downstream effects of drug action by overlaying public data on user-generated networks

Our system uses millions of curated literature findings from QIAGEN Knowledge Base and the OmicSoft digital warehouse. This discussion is intended for both those familiar with QIAGEN IPA and newcomers interested in learning more.

Mining curated knowledge graphs and validating with experimental datasets to...

Mon, 11 Dec 2023 13:14:15 GMT

In an era of near-limitless public experimental data but little standardization, meaningful insights are lost to noise. Large collections of quality experimental data are essential for big-picture discoveries that stand up to scrutiny.

In this webinar, you will learn how to feed your drug discovery programs by integrating connections mined from QIAGEN Biomedical Knowledge Base with deeply-curated disease datasets from QIAGEN OmicSoft Lands.

Combining unified 'omics datasets with contextual relationship evidence from our knowledge graph, we will address complex questions such as:
• Which genes aren't expressed in normal tissue, yet are expressed in diseases of interest, based on experimental evidence?
• Which of these proteins are cell surface proteins, with evidence for extracellular localization?
• How are these proteins related directly or indirectly to disease pathways, and can these be connected to known drug targets?
• Can we identify correlated biomarkers, mutation targets, clinical factors or other means of cohort selection?

Exploring pan-cancer immunomodulators for biomarker discovery and validation...

Thu, 12 Oct 2023 18:00:00 GMT

Cancer outcome is influenced by both the tumor microenvironment and host immune response. Using QIAGEN OmicSoft Studio to access public data from The Cancer Genome Atlas (TCGA) and our human Single Cell Lands collection, you’ll learn how to:

• View host immune response clusters across TCGA samples
• Identify differentially expressed immunomodulators across sample groups
• Visualize single-cell dimension reduction maps and overlay expression data
• Identify potential biomarkers whose expression correlates or anti-correlates with targets genes
• Validate new biomarkers using custom queries and TCGA survival data

Cross-species comparison and validation for drug discovery and biomarker...

Wed, 27 Sep 2023 14:11:02 GMT

Some human studies may be unfeasible or unethical, making cross-species research critical for drug discovery and biomarker validation. Cross-species research is a crucial method to collect data to examine potential toxicity for a candidate drug, determine the efficacious doses that may be suitable for humans, identify potential biomarkers for a disease of interest or a therapeutic response and understand the mechanisms of disease or treatment. While animal models and humans have similar anatomy and physiology, the subtle differences among organisms in the animal kingdom need to be considered and data collected must be interpreted using a meaningful method.

Using QIAGEN IPA, you can perform comparative analyses across various animal models, even combining different time points, treatments, tissues and cell types with data generated from a wide variety of ‘omics technologies (RNA-seq, scRNA-seq, proteomics, metabolomics, etc.). In this training, you will learn how to:
1. Generate activity heatmaps and expression charts comparing different pathways and regulatory networks across different species
2. Use Activity Plot, Pattern Search and Analysis Match to compare your own data against thousands of public data pre-curated and pre-analyzed representing an array of disease states, conditions and other biological conditions
3. Create expression and correlation plots using pre-curated and pre-analyzed public data to validate and confirm findings derived from a comparison analysis

Indication Expansion and Repurposing of PIK3CA Kinase Inhibitors: Systems...

Wed, 20 Sep 2023 07:38:56 GMT

Here we demo tools to rapidly guide drug repurposing and indication expansion, using alpelisib—a PI3Kα inhibitor approved for metastatic breast cancer—as a case study. The speaker shows how activating mutations in the PIK3CA gene, a key oncogene, not only prevalent in breast cancer but also significantly present in oral cancers, an area with few active clinical trials and limited therapeutic development. By merging real-world mutation data, clinical outcomes, and pathway-based network modeling, the analysis shows that PIK3CA mutations in oral cancer correlate with poorer survival, and that inhibiting PIK3CA activity could reduce disease progression. Further, the session used public dataset comparisons to identify non-oncologic diseases (e.g., lupus, heart disease) that share similar biology, suggesting future repurposing potential. It concluded by identifying possible combination therapy partners through anti-matching expression patterns, showcasing a full workflow from hypothesis generation to target validation in under an hour.

Drug treatment, toxicology and target safety assessment using QIAGEN IPA and...

Wed, 06 Sep 2023 16:20:38 GMT

In this 90-minute training, you'll learn how to perform drug treatment, toxicology and target safety assessment-related discoveries using QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN Omicsoft Lands.

Using public data from GTEx (normal tissue), GEO, cancer collections and more, you'll learn how to use Omicsoft Lands to:
• Investigate a drug target or biomarker expression across different normal tissues, disease conditions, treatments and more
• Correlate the expression of two or more genes
• Identify a list of genes or biomarkers specific to treatment, disease, normal tissue, cell type and more

Using findings from peer-reviewed publications and other sources, we'll explore with you how to use QIAGEN IPA to:
• Study the impact of targeting a gene/protein on different toxicological and biological functions
• Derive toxicity findings for a gene of interest from QIAGEN IPA's knowledgebase
• Identify and study toxicity-related pathways, regulators and functions for an internal dataset or a public dataset
• Compare different drug treatments, other conditions or multi-omics data for novel discoveries

Interpreting genetic risk loci from GWAS in the context of key genes and...

Wed, 16 Aug 2023 14:00:59 GMT

Genome-wide association studies (GWAS) provide insights into the genetic architecture of disease by identifying susceptibility loci for the disease within a population. If you'd like to identify disease genes and novel biological pathways that underlay the disease pathogenesis to identify novel drug targets, QIAGEN Ingenuity Pathway Analysis (IPA) helps you characterize and validate risk loci within a biological context. In this training, you'll discover how to perform a core analysis for a list of risk loci to study their association with different pathways and regulatory networks.

You'll learn how to:
• Upload and perform a core analysis on a list of GWAS risk loci
• Investigate pathways and regulatory networks to understand biological mechanisms
• Compare enrichment between risk loci analysis to identify biological similarities and difference
• Identify commonalities and differences between risk loci list
• Generate a custom network and contextualize it using public data
• Export high-resolution images and comprehensive tabular results in preferred formats

Indication expansion and drug repurposing using QIAGEN OmicSoft and Ingenuity...

Wed, 16 Aug 2023 13:59:37 GMT

Research and development for new drugs and disease treatments can be lengthy and costly. Indication expansion can help broaden the impact of a new drug that has already been through the arduous R&D process for a disease or cancer. Drug repurposing can take this concept and expand on it by looking for other diseases with similar drug target biology. The logic is if they share similar target biology, they may benefit from the same treatment.

During this training, we'll cover skills such as:
• Querying QIAGEN OmicSoft Lands data from sources like TCGA or ICGC and exploring the incidence of a cancer-driving somatic mutation that is targeted by a treatment
• Creating a cohort of patients within OmicSoft with a disease-causing mutation and wild type for the gene of interest
• Generating survival curves for each mutant and wild type group for various indications in the relevant OmicSoft Land
• Using QIAGEN Ingenuity Pathway Analysis (IPA) to generate a mechanism of action network for the drug's target
• Exploring various network overlay features to enable in silico testing and combination drug partner investigation
• Searching for publicly available datasets relevant to your chosen indication
• Comparing the expression profile from our disease state with other publicly available analyses to find other indications or diseases that share similar biology

Target exploration and cell line selection for drug discovery

Fri, 21 Jul 2023 15:07:32 GMT

Cancer cell line models have been a cornerstone of cancer research for decades. Profiling cancer cell lines is a powerful tool to identify gene alterations or cancer-related pathways and to discover potential drug targets. This training will focus on using QIAGEN OmicSoft Lands and Ingenuity Pathway Analysis (IPA) as guides to select cell lines and translate insights gained from cell lines into discovering new possible drug targets.
In this 90-minute training, we’ll explore how you can use our platforms to:
• Select appropriate cancer cell lines for a variety of applications such as drug discovery, precision disease modeling, understanding gene function in cancer and immune-oncology research
• Examine genes of interest across various ‘omics datasets to analyze changes in expression, mutation, hotspots and gene dependency data
• Generate networks for hypotheses and test them in-silico to improve the translation of insights derived from cell line models to drug target identification
• Analyze integrated public 'omics data and drug response phenotypes using cell line model systems by exploring data from the Library of Integrated Network-Based Cellular Signatures (LINCS)
• Prioritize drug targets and profile phenotypic/downstream effects of drug action by overlaying public data on your own generated networks

Our system uses millions of curated literature findings in the QIAGEN/ IPA Knowledge Base and the OmicSoft digital warehouse. This training is for those of you familiar with QIAGEN IPA, as well as newcomers interested in learning more.

Study of public data on inflammatory conditions public data for biomarker and...

Thu, 22 Jun 2023 16:57:17 GMT

In this 90-minute training on QIAGEN OmicSoft and Ingenuity Pathway Analysis (IPA), we’ll coveryou’ll learn how to easily query inflammatory conditions related to public data (GEO, SRA and more) so you canto: • Rapidly query and identify public datasets that fit your search criteria • Discover and validate biomarker expression in disease tissue, different treatments and response groups • Identify a list of biomarkers specific to a condition (non-responders, disease-specific, cell-type specific and more) • Confirm condition-specific biomarkers through gene expression heatmaps • Investigate biological mechanisms through network study
Additional QIAGEN Digital Insights scientists will be on the call to answer your questions and help with other inquiries, such as how to install the software, etc.

Checkpoint inhibitors in the context of biomarkers, drug targets and pathways

Thu, 11 May 2023 20:00:00 GMT

In this training, we will focus on how you can use QIAGEN Omicsoft Studio and QIAGEN Ingenuity Pathway Analysis (IPA) to discover new biomarkers, validate (or study) drug targets and identify novel mechanisms of action with your own and/or public checkpoint inhibitor datasets from resources like GEO, SRA, TCGA and more.

In this training, you’ll learn how to:

· Investigate the expression of a gene/biomarker/drug target across different treatments and diseases

· Derive a biomarker/gene signature from a specific condition (for example, non-responders of a drug, or a particular disease/disease subtype and others)

· Correlate expression of multiple genes and biomarkers

· Compare different experimental groups (e.g., your own data and/or public data) at both the levels of gene expression and pathways/regulatory networks activity

Biomarker discovery and disease pathology investigation using OmicSoft and...

Thu, 16 Mar 2023 16:01:02 GMT

In this training, attendees will learn how to harness curated ‘omics datasets in OmicSoft DiseaseLand and curated research findings in IPA to discover new potential biomarkers. Using a neurological disorder as a case study, we will:

• Search public RNA-Seq datasets for tissue- and disease-specific differential expression in brain
• Identify genes whose expression correlates with our factor within a sample group
• Prioritize candidate biomarkers by disease vs. normal expression
• Simulate biomarker activity changes to determine potential mechanisms of action
Investigation of inflammatory, infectious, oncological, and other disorders can also be done using similar approach and will be highlighted during this training.

Drug treatment data investigation using Omicsoft and Ingenuity Pathway Analysis

Thu, 02 Mar 2023 15:19:00 GMT

In this training, the trainer will go over how to utilize public drug treatment data from GEO, LINCS, and other sources to do discoveries regarding drug treatment investigation, biomarker discovery and validation. We will also use IPA to gain insight on the biological mechanisms of these treatments.

Participants will learn how to:
• Easily search for public studies relevant to drug treatment of their interest
• Identify a list of key genes/biomarkers relevant to a treatment or pathological condition
• Send differential expression data to Ingenuity Pathway Analysis to investigate biological mechanism (underlying disease pathology, drug response and more)
• Generate expression, correlation, heatmap and other plots to investigate key genes and biomarkers
• Explore other treatments that may share similar gene expression patterns

Investigating biomarkers and drug targets from public data using QIAGEN...

Fri, 17 Feb 2023 14:50:39 GMT

In this 90-minute webinar, we’ll cover how to easily query non-oncology public data (GEO, SRA and more) to:
• Rapidly query and identify public datasets that fit our search criteria
• Discover and validate biomarker expression in disease tissue, different treatments and response groups
• Identify a list of biomarkers specific to a condition (non-responders, disease-specific, cell-type specific and more)
• Confirm condition-specific biomarkers through gene expression heatmaps
• Investigate biological mechanisms through network study

Discoveries from public immuno-oncology studies using Omicsoft and Ingenuity...

Thu, 12 Jan 2023 17:24:47 GMT

This training will focus on how QIAGEN Omicsoft Studio and Ingenuity Pathway Analysis (IPA) can be used to discover new biomarkers, validate (or study) drug targets and identify novel mechanism of action with user and/or public Immuno-Oncology studies from resources like GEO, SRA, TCGA and more.
Attendees will learn how to
• Investigate expression of a gene/biomarker/drug target across different treatments and diseases
• Derive a biomarker/gene signature from specific condition (example non-responders of a drug, a specific disease/disease subtype and more)
• Correlate expression of multiple genes and biomarkers
• Compare different experimental groups (user and/or public data) at both gene expression and pathways/regulatory networks activity levels

Somatic variants investigation in critical regulatory pathways

Thu, 25 Aug 2022 15:10:11 GMT

This training will focus on using QIAGEN Ingenuity Pathway analysis (IPA) and Human Somatic Mutation Database (HSMD) to identify key somatic variants associated with regulatory genes in ‘omic data and study the genomic characteristics of both target and disease to better understand the clinical relevance. Identifying and studying the genomic characteristics of drug targets and important genes are of great interest to many researchers as it can offer new insights into improving drug discovery and precision medicine. In this 90-minute training, the Human Somatic Mutation Database (HSMD) will be introduced for genomic investigation. HSMD is a web-based database containing data for hundreds of thousands of variants within the context of solid tumors and hematological malignancies. Specifically, HSMD provides gene-level, alteration-level, and disease-level information including clinically observed gene and variant frequencies across cancer types.

Attendees will learn how to:

· Use IPA to identify key regulators within a dataset of interest

· Use HSMD to investigate variants for target genes and cancer type of interest

· Synthesize key findings from drug labels, clinical trials, and PubMed articles for specific alterations and cancer types

Click here to learn more about HSMD and IPA.

Knowledge graphs and more: Analytics-driven drug discovery using advanced...

Tue, 19 Jul 2022 16:01:43 GMT

High-quality biomedical relationships knowledge is the cornerstone of modern and innovative data- and analytics-driven drug discovery. Yet this knowledge is locked in thousands of publications and dozens of databases. This webinar will show you how to unlock this knowledge and use it to strengthen your efforts in data science-driven drug discovery.

In this webinar, you'll learn about:

High-quality biomedical relationships knowledge: What it is and how to access it
Knowledge graphs and knowledge graph analysis
Artificial intelligence (AI)-driven target identification and drug repositioning using knowledge graphs and biomedical relationships
Disease subtyping and biomarker identification based on functional features
Target, disease and drug intelligence portals: Application development and data integration leveraging biomedical relationships

Don't miss this opportunity to discover how to give your drug discovery programs a data science-driven advantage by leveraging high-quality biomedical relationships knowledge.

Drug repurposing: from large-scale biological data to therapeutics

Fri, 08 Jul 2022 14:34:00 GMT

One of the challenges we are facing today is the high cost and slow pace of drug development for many disease areas such as cancer, CNS, rare diseases etc. Repurposing drugs for new indications will have a shorter developmental time, lower cost, and less safety risk than the traditional drug development process.

Join us for this 60-minute Webinar on Drug repurposing: from large-scale biological data to therapeutics. This one-hour event will show how our platform enables biologists to leverage transcriptomics and literature-curated biological data for in-silico drug repositioning and repurposing.

Through a series of short demonstrations, we will explore:
• A systems biology approach to discover new uses of existing FDA-approved drugs
• Accelerate drug discovery process and generate novel hypotheses from high-quality omics and literature curated data
• Estimate network of genes potentially perturbed by drugs and integrate it with drug and disease gene expression signatures
• Study how targets of interest are expressed across different diseases and tissues

Our system uses millions of curated literature findings in the QIAGEN/ IPA knowledgebase and the OmicSoft digital warehouse. The presentation is intended for both those familiar with Ingenuity Pathway and newcomers interested in learning more.

Target discovery through QIAGEN IPA and HSMD

Fri, 13 May 2022 15:18:03 GMT

Identifying and studying the genomic characteristics of drug targets and important genes are of great interest to many researchers as it can offer new insights into improving drug discovery and precision medicine. In this 90-minute training, QIAGEN Human Somatic Mutation Database (HSMD) will be introduced for genomic investigation. HSMD is a web-based database containing data for hundreds of thousands of variants within the context of solid tumors and hematological malignancies. Specifically, HSMD provides gene-level, alteration-level, and disease-level information including clinically observed gene and variant frequencies across diseases. Accordingly, this webinar will focus on using QIAGEN Ingenuity Pathway analysis (IPA) and HSMD to identify key regulators in ‘omic data and study the genomic characteristics and landscape of both target and disease.

Attendees will learn how to:
• Use IPA to identify key regulators within a dataset of interest
• Use HSMD to investigate variants for target genes and diseases of interest
• Synthesize key findings from drug labels, clinical trials, and PubMed articles for specific alterations and diseases

Human-certified ‘omics data to power drug discovery

Thu, 24 Feb 2022 17:02:21 GMT

Integrating external and internal ‘omics data is a key element of hypothesis generation, target identification, and biomarker prioritization when it comes to drug discovery. It is never as straightforward as it seems and usually costs more, takes more time than anticipated, often with poor results. In this talk, Joseph Pearson, PhD, from QIAGEN Digital Insights will discuss approaches and resources to overcome these obstacles and improve outcomes.

Participants will learn:
• Where automated curation approaches can leave you short
• Why data scientists spend most of their time not doing data science
• Where bioinformaticians and data scientist spend most of their time
• What is required of high-quality ‘omics data
• Example of high-quality TCGA data
• How to extend these practices to internal data structures

To learn more visit: https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/qiagen-omicsoft